How Superdrol (Methasterone) Affects HDL Cholesterol

Superdrol (methasterone) is a 17-alpha-alkylated oral AAS with extremely high androgenic potency per milligram. Its HDL suppression arises from multiple converging factors:

1. Potent first-pass HTGL upregulation: The 17-AA structure allows superdrol to survive hepatic first-pass metabolism intact, delivering a concentrated, sustained androgenic signal to hepatocytes. This powerfully upregulates hepatic triglyceride lipase (HTGL), the enzyme that catabolises HDL particles.
2. No aromatisation: Superdrol does not convert to estradiol. Estradiol normally suppresses HTGL gene expression and supports apolipoprotein A-I (ApoA-I) production. The complete absence of estrogenic activity means there is no counterbalance to androgenic HTGL stimulation.
3. ApoA-I suppression: Like other 17-AA orals, superdrol reduces ApoA-I production, impairing de novo HDL particle synthesis alongside the accelerated catabolism.
4. Extremely high potency per milligram: Superdrol has an anabolic-to-androgenic ratio that does not protect the liver from its androgen-receptor-mediated effects. The hepatic androgenic signal is disproportionately high for the dose, making even 10 mg/day sufficient to produce severe lipid changes.

The combination of maximum first-pass hepatic androgenic loading, zero estrogenic offset, and direct ApoA-I suppression places superdrol at the extreme end of oral steroid lipid toxicity.

At 10-20 mg/day (typical doses):

• Severe HDL suppression: 50-80% reduction from baseline within 2-4 weeks
• Single-digit HDL values (below 10 mg/dL) are commonly reported at these doses
• A pre-cycle HDL of 50 mg/dL may fall to 5-15 mg/dL
• LDL simultaneously rises, creating a severely atherogenic total cholesterol:HDL ratio
• The total cholesterol:HDL ratio can easily exceed 10:1, far above the high-risk threshold of 5.0

At the low end (10 mg/day):

• Significant suppression still occurs, typically within the first week as HTGL upregulation is rapid
• Do not assume 10 mg/day is "safer for lipids"; the dose-response curve starts steeply

Timing:

• First-pass mechanism means measurable HTGL changes within 24-72 hours
• Significant HDL falls documented within the first week
• Maximum suppression often reached by weeks 2-3

Baseline lipid panel is mandatory:

• Establish HDL, LDL, triglycerides, and total cholesterol before starting
• Do not start superdrol if baseline HDL is already below 40 mg/dL; the additional suppression will push you into critical territory

On cycle (mandatory mid-cycle testing):

• Check lipids at 2 weeks. Given the severity and speed of suppression, end-of-cycle panels alone are insufficient.
• If HDL has fallen below 15 mg/dL at week 2, strongly consider stopping the compound
• If HDL has fallen below 10 mg/dL, discontinuation is strongly recommended

Post-cycle:

• Recheck at 4 weeks post-cessation and again at 8-12 weeks to confirm recovery
• If HDL remains below 20 mg/dL at 6 weeks post-cycle, consult a physician for cardiovascular risk assessment

Cycle length limitation:

• Limit superdrol cycles to 3-4 weeks maximum. Duration of atherogenic lipid exposure is as important as peak suppression.
• Some users run 2-week superdrol cycles for this reason

Supplement protocol during use:

• Omega-3 EPA/DHA: 3-4 g/day (start before beginning the cycle if possible)
• Citrus bergamot: 1,000 mg/day
• Psyllium husk: 5-10 g/day with meals (soluble fibre reduces LDL and supports lipid balance)
• These supplements mitigate but do not eliminate the lipid damage at bodybuilding doses

Post-cycle continuation:

• Continue all lipid supplements for 8-12 weeks post-cycle
• Increase cardiovascular exercise volume post-cycle: 45+ minutes of moderate-intensity cardio, 5+ days/week is the most effective HDL-raising intervention

Stacking prohibition:

• Never combine superdrol with other oral 17-AA compounds. Adding stanozolol, oxymetholone, or methandrostenolone creates additive hepatotoxicity and additive HTGL stimulation. The resulting lipid profile is catastrophic.
• Never stack superdrol with other hepatotoxic compounds (alcohol, high-dose NSAID use)